CellCentric Company
CellCentricвАЩs primary programme targets a deubiquitinase (DUB) enzyme which is strongly associated with prostate cancer, a leading cause of mortality among men. The target modulates the androgen receptor pathway and can potentially combat the multiple resistance mechanisms seen with recently approved prostate cancer drugs such Xtandi and Zytiga. The programme also has potential clinical utility in non-small cell lung, breast and colon cancer.
Founded Date:
2003
Total Funding:
$42.6M
Investor Type:
Company
Employee Number:
1-10
Investment Stage:
N/A
Funding Status:
N/A
Number Of Exists:
Venture - Series Unknown
Technology:
Data-driven Technologies
Last Funding Type:
Venture - Series Unknown
Investors Number:
9
Industry:
PharmTech
Headquarters:
Cambridge, Cambridgeshire, United Kingdom
Estimated Revenue:
$10M to $50M